How to Recognize Tysabri-Related PML Symptoms: A Clinical Guide

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Information to Targeted Risk Awareness

If you or a loved one is taking Tysabri, recognizing the early symptoms of progressive multifocal leukoencephalopathy (PML) can be critical. This page outlines the clinical patterns of PML symptoms, drawing on decades of medical research into treatment-related risks, to help you understand what to watch for and when to contact a healthcare provider.

Find Out If You Qualify for Compensation →

Understanding Tysabri and Its Association with PML

Tysabri (natalizumab) is a biologic medication approved as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease. Its prescribing information carries a boxed warning stating that Tysabri increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain caused by the JC virus that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). PML occurs in patients who are immunocompromised, and three specific risk factors have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Healthcare professionals are instructed to monitor patients for any new sign or symptom suggestive of PML and to withhold Tysabri immediately at the first such indication (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Because of this risk, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The clinical presentation of PML can include progressive neurological deficits such as weakness, gait disturbance, cognitive impairment, and visual changes. In the FDA Adverse Event Reporting System (FAERS), the most frequently reported adverse events associated with Tysabri include fatigue, multiple sclerosis relapse, headache, gait disturbance, fall, memory impairment, asthenia, malaise, balance disorder, hypoesthesia, muscular weakness, cognitive disorder, and mobility decreased (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). These symptoms overlap with those of multiple sclerosis itself, which can delay recognition of PML. The boxed warning emphasizes that PML usually leads to death or severe disability, underscoring the gravity of this adverse effect (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Mechanism of Action and Risk Factors for PML

The mechanistic pathway linking Tysabri to PML involves its action as an alpha-4 integrin antagonist. Tysabri binds to alpha-4 integrin on the surface of immune cells, preventing their migration across the blood-brain barrier into the central nervous system. This reduces inflammatory activity in multiple sclerosis but also impairs immune surveillance against the JC virus in the brain. In immunocompromised individuals, the JC virus can reactivate and cause lytic infection of oligodendrocytes, leading to demyelination and the characteristic lesions of PML. The risk is highest in patients who are anti-JCV antibody positive, have been on Tysabri for more than two years, or have previously used immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). For patients who develop PML after Tysabri exposure, legal considerations may arise regarding the adequacy of warnings provided by the manufacturer. The prescribing information includes a boxed warning that clearly states the increased risk of PML and identifies the three risk factors (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). However, questions may be raised about whether patients and healthcare providers were adequately informed about the magnitude of this risk, the importance of regular monitoring, and the need for prompt discontinuation at the first sign of PML. The boxed warning instructs that Tysabri should be withheld immediately at the first sign or symptom suggestive of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Failure to follow these instructions could contribute to delayed diagnosis and worse outcomes.

Statute of Limitations for Tysabri-Related Claims in Massachusetts

In Massachusetts, the statute of limitations for personal injury claims, including those related to pharmaceutical products, is generally three years from the date the injury is discovered or reasonably should have been discovered. For PML associated with Tysabri, the timeline between exposure and documented harm can vary. PML typically develops after months to years of Tysabri treatment, with risk increasing after two years of therapy (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The onset of symptoms may be insidious, and diagnosis often requires MRI imaging and cerebrospinal fluid analysis for JC virus DNA. Once diagnosed, the harm is severe and often irreversible. Affected patients or their families should consult with an attorney experienced in pharmaceutical litigation to determine the applicable statute of limitations in their specific case, as the clock may start ticking from the date of diagnosis or from when the connection to Tysabri was reasonably suspected.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.

Frequently Asked Questions

What is the statute of limitations for Tysabri-related PML claims in Massachusetts?

In Massachusetts, the statute of limitations for personal injury claims, including those related to Tysabri, is generally three years from the date the injury is discovered or reasonably should have been discovered. For PML, this may be the date of diagnosis or when the connection to Tysabri was suspected. It is important to consult an attorney promptly.

What are the risk factors for developing PML while on Tysabri?

The three identified risk factors are: presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Find Out If You Qualify for Compensation

Statutes of limitations can limit the time you have to file a claim. A records screening is free and confidential.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.